רווח תפעולי לפני פחת: Soligenix, Inc. (SNGX)

Risks for Soligenix, Inc. (SNGX) are linked to a dependence on government contracts for antidotes and the commercialization of orphan drugs. The consolidated EBITDA serves as a stability indicator, with the metric currently standing at 0.00. The orphan drug market and ricin vaccines provide the primary support. Full laboratory capacity stabilizes the situation, minimizing downtime during clinical trials.

Soligenix, Inc. (SNGX) development of thermostable vaccines and countermeasures against biotreats requires colossal expenditures, making the monitoring of actual cash flows critically important. By analyzing EBITDA in cash terms, an investor sees an operating result stripped of accounting assumptions, which confirms the actual effectiveness of the business model and the execution of company plans, eliminating speculative expectations when assessing the asset's value.